文献速递甲状腺疾病

替妥木单抗治疗病程长且疾病活动度低的甲状腺眼病患者的疗效与安全性

Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

这项在美国11个中心开展的随机双盲安慰剂对照试验纳入62例病程2至10年、临床活动度评分≤1的甲状腺眼病患者,按2:1随机接受替妥木单抗或安慰剂静脉输注(每3周一次,共8次)。第24周时替妥木单抗组突眼改善优于安慰剂组,差异为-1.48(95%CI -2.28, -0.69;P=.0004),两组不良事件发生率相似。

要点

  • 替妥木单抗组第24周突眼改善最小二乘均值-2.41(SE 0.228),安慰剂组-0.92(SE 0.323),差异-1.48(95%CI -2.28, -0.69;P=.0004)。
  • 两组不良事件发生率相似;高血糖替妥木单抗组6例(15%)vs 安慰剂组2例(10%)。
  • 听力损害替妥木单抗组9例(22%)vs 安慰剂组2例(10%)。

核心结论

  • 替妥木单抗在病程长且炎症低的甲状腺眼病患者中较安慰剂显著改善突眼,疗效不受疾病病程或活动度影响,安全性特征与既往报道相当。

研究设计与样本

  • 随机双盲安慰剂对照试验,在美国11个中心开展,纳入成人甲状腺眼病患者,病程2至10年,临床活动度评分≤1或突眼/复视无额外炎症或进展≥1年,突眼较甲状腺眼病前和/或正常值≥3 mm,甲状腺功能正常或轻度减退/亢进,既往未接受替妥木单抗,基线前3周内未使用类固醇。
  • 患者按2:1随机接受静脉替妥木单抗或安慰剂,每3周一次,共8次输注;主要终点为第24周突眼(mm)改善。
  • 共62例患者随机分组,替妥木单抗组42例,安慰剂组20例。

主要发现

  • 第24周突眼改善最小二乘均值(SE):替妥木单抗组-2.41(0.228) vs 安慰剂组-0.92(0.323),差异-1.48(95%CI -2.28, -0.69;P=.0004)。
  • 不良事件发生率两组相似;高血糖替妥木单抗组6例(15%) vs 安慰剂组2例(10%)。
  • 听力损害替妥木单抗组9例(22%) vs 安慰剂组2例(10%)。
  • 不良事件导致停药:替妥木单抗组1例(左耳传导性听力丧失伴先天性异常),安慰剂组1例(输注相关);无死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Early inflammatory thyroid eye disease (TED) can lead to symptomatic chronic disease, including disabling proptosis. Teprotumumab, an insulin-like growth factor-1 receptor (IGF-1R) inhibitor, previously demonstrated efficacy in acute, high-inflammation TED trials. OBJECTIVE: We present data from the first placebo-controlled trial with teprotumumab in chronic/low disease activity TED. METHODS: This randomized double-masked, placebo-controlled trial, conducted at 11 US centers, enrolled adult participants with TED duration of 2 to 10 years, Clinical Activity Score (CAS) ≤ 1 or no additional inflammation or progression in proptosis/diplopia for ≥1 year, proptosis ≥3 mm from before TED and/or from normal, euthyroid/mildly hypo/hyperthyroid, no prior teprotumumab, and no steroids within 3 weeks of baseline. Patients received (2:1) intravenous teprotumumab or placebo once every 3 weeks (total 8 infusions). The primary endpoint was proptosis (mm) improvement at Week 24. Adverse events (AEs) were assessed. RESULTS: A total of 62 (42 teprotumumab and 20 placebo) patients were randomized. At Week 24, least squares mean (SE) proptosis improvement was greater with teprotumumab (-2.41 [0.228]) than with placebo (-0.92 [0.323]), difference -1.48 (95% CI -2.28, -0.69; P = .0004). Proportions of patients with AEs were similar between groups. Hyperglycemia was reported in 6 (15%) vs 2 (10%) and hearing impairment in 9 (22%) vs 2 (10%) with teprotumumab and placebo, respectively. AEs led to discontinuation in 1 teprotumumab (left ear conductive hearing loss with congenital anomaly) and 1 placebo patient (infusion-related). There were no deaths. CONCLUSION: Teprotumumab significantly improved proptosis vs placebo in longstanding/low inflammation TED, demonstrating efficacy regardless of disease duration/activity. The safety profile was comparable to that previously reported.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Douglas RS, Couch S, Wester ST, et al. Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity. J Clin Endocrinol Metab. 2023. PMID: 37925673. doi:10.1210/clinem/dgad637

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。